67th annual Meeting of the American Academy of DermatologySan Francisco, California, USA, 6–10 March 2009

被引：4
作者：
Kathy Fraser
机构：
[1] Wolters Kluwer Health / Adis,
来源：
American Journal of Clinical Dermatology | 2009年 / 10卷 / 3期
关键词：
Psoriasis; Acne; Hemangioma; Tumor Necrosis Factor Inhibitor; Actinic Keratosis;
D O I：
10.2165/00128071-200910030-00009
中图分类号：
学科分类号：
摘要：
This year’s annual meeting of the American Academy of Dermatology was attended by over 18 500 international delegates, and featured presentations from world-renowned leaders in the field of dermatology, including research in the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails.
引用
收藏
页码：205 / 210
页数：5
相关论文
共 80 条
[1]  
Krueger GG(2007)A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis N Engl J Med 356 580-92
[2]  
Langley RG(2008)Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 1675-84
[3]  
Leonardi C(2009)A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis [poster no. 3318] J Am Acad Dermatol 60 166-7
[4]  
Papp KA(2008)ABT-874 Psoriasis Study Investigators Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial 144 200-9
[5]  
Langley RG(2009)Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial [poster no. 3326] J Am Acad Dermatol 60 168-38
[6]  
Lebwohl M(2008)The PKC inhibitor AEB071 may be a therapeutic option for psoriasis J Clin Invest 118 3151-42
[7]  
Griffiths C(2008)An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast Curr Med Res Opin 24 1529-35
[8]  
Menter A(2008)Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study Lancet 371 1337-33
[9]  
Strober B(2007)Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies J Drugs Dermatol 6 428-51
[10]  
Kimball AB(2003)Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg/g ointment and calcipotriol 50 microg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas Br J Dermatol 148 326-5
12345678